Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
ACT 4 study initiated in acute treatment of atrial fibrillation
November 18th, 2005
Cardiome Pharma Corp. (CRME, COM) and its partner Astellas Pharma U.S., Inc., announced the initiation of an open-label safety study of intravenous RSD1235 for the acute treatment of atrial fibrillation. The study, called ACT 4 (Atrial arrhythmia Conversion Trial 4) will evaluate the safety of intravenous RSD1235 in approximately 120 atrial fibrillation (AF) patients. There is no placebo or active control group in the study, which is being conducted by Astellas and carried out across approximately 30 centers in the U.S., Canada, and Europe. ACT 4 is primarily a safety study and it is anticipated that the added safety data will supplement the pivotal ACT 1 and ACT 3...
Source: Drug Week (2005-11-18)
|
